India's Expert Group Says Denying Patents To Incremental Innovations Will Not Be TRIPS-Compliant; Evergreening To Be Scrupulously Prevented
This article was originally published in PharmAsia News
MUMBAI - Putting to rest wide speculation about applicability of the controversial Section 3 (d) of the Indian Patents Act, which deals with the treatment of incremental innovations, the Mashelkar Committee report - set up to dwell on Indian patent law issues - has recommended that incremental innovations should be encouraged
You may also be interested in...
MUMBAI - Hopes for Novartis to obtain a product patent for its chronic myeloid leukemia drug Gleevec (imatinib) were dashed after India's Intellectual Property Appellate Board ruled that Novartis' patent application covering the medicine's beta-crystalline version is not patentable because it failed to satisfy the requirements under Section 3(d) of the India Patents Act
Insider Analysis From Nishith Desai Associates: Learning And Unlearning From Section 3(d) Of The Indian Patents Act (Part 2 of 2)
By Milind Antani and Gowree Gokhale, Nishith Desai Associates, Mumbai, Indi
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).